Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's core products are experiencing steady growth, while short-term profits are under pressure due to the performance of the hearing aid segment [5][7] - The company is expected to focus on core products and self-manufactured items, with a rich product pipeline that is likely to enhance profitability in the future [7] Financial Performance Summary - For 2023, the company reported revenue of 2,854 million RMB, with a year-on-year decline of 4.14%. The net profit attributable to the parent company was 254 million RMB, down 15.71% year-on-year [6] - Revenue is projected to grow to 3,495 million RMB in 2025, representing a year-on-year increase of 17.15%. The net profit is expected to reach 376 million RMB, with a growth rate of 20.45% [6][8] - The gross margin for 2024 is reported at 51.9%, an increase of 8.6 percentage points year-on-year, with significant improvements in the rehabilitation aids segment [7] Business Segment Performance - The rehabilitation aids segment achieved revenue of 1.1 billion RMB, up 42.8% year-on-year. The traditional Chinese medicine therapy and other segments generated 180 million RMB, up 20.5% year-on-year [7] - The hearing aid segment reported revenue of 270 million RMB, a year-on-year increase of 37.9%, but also faced a net loss of 43.25 million RMB due to a challenging consumer environment and new store performance [7] Profitability and Valuation - The company is expected to see net profits of 3.8 billion RMB, 4.5 billion RMB, and 5.4 billion RMB from 2025 to 2027, with growth rates of 20.4%, 20.2%, and 20.6% respectively [7] - The current price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 19X, 16X, and 13X respectively [7]

可孚医疗 20250428 摘要 • 2024 年公司净利润同比增长 36.74%至 2.75 亿元，经营活动现金流增长 68.45%至 6.63 亿元，综合毛利率提升至 51.86%。公司维持高分红政策， 年度现金分红总额达 3.66 亿元，显示了良好的盈利能力和对股东的回报。 • 2024 年主营业务收入 28.42 亿元，线上渠道占比 66%，线下渠道占比 28%。康复辅具、医疗护理和健康监测为主要收入来源，分别占比 37%、26.86%和 6.39%。线上渠道的强势表现，尤其是抖音、快手等兴 趣电商，成为增长亮点。 • 2025 年一季度营收同比下降 8%至 7 亿元，归母净利润同比下滑 9%至 0.9 亿元。医疗护理和健康监测品类实现超过 10%的增长，而康复辅助和 呼吸支持类产品则出现下降，尤其是呼吸支持类产品降幅接近 50%。 • 公司深化核心品类战略，优化资源配置，提升运营效率。助听器、口腔护 理和耳鼻喉护理等核心品类持续增长，成为业绩主要驱动力。通过价值链 管理协同降本增效，强化供应链管理体系，巩固核心品类竞争优势。 • 公司积极参与国家补贴政策，参与国补的品类在补贴期间整体业绩有明显 增长 ...